Dr. Cristofanilli has collaborated with Dr. Yang in the clinical study design and will be responsible for the study review and regulatory approval and monitoring. He will identify and consent patients with advanced disease candidates for the study as for inclusion criteria. Patients will have baseline and longitudinal blood collections according to study schedule. The specimens will be collected and handled by his laboratory team and circulating tumor cells (CTCs) isolated using available sorting technologies. Additional plasma and serum specimens are stored and his clinical research team will also update and maintain detailed clinical database.
|Effective start/end date||8/15/17 → 7/31/22|
- Thomas Jefferson University (080-27000-S27101//5R01CA207468-02)
- National Cancer Institute (080-27000-S27101//5R01CA207468-02)